Livestock vaccines Market Outlook 2026–2035: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines livestock vaccines for poultry, swine, cattle and small ruminants, with a focus on the programmes for avian influenza and African swine fever that are moving governments from culling toward vaccination. It tests how fast licences and government decisions turn into vaccinated animals, and which participants capture value among animal health companies, specialist vaccine makers, governments and producers.

Avian influenza has pushed the United States toward vaccination. The USDA Center for Veterinary Biologics granted Zoetis a conditional licence on 13 February 2025 for an avian influenza vaccine in chickens, a killed H5N2 virus designed to match circulating H5 strains and to let vaccinated birds be told from infected birds. More than 767 commercial flocks and 166 million birds had been affected since 2022 by March 2025, and 976 cases had been reported in dairy cattle across 17 states. The conclusion is that outbreaks have moved vaccines from a contingency to an active policy option, and a conditional licence is the route by which new vaccines reach the market fastest.

A licence does not decide use. The decision to vaccinate commercial flocks rests with national authorities in consultation with local poultry sectors, and USDA must separately approve deployment. The broiler industry opposes mass vaccination because about 16% of US chicken meat production is exported, while the egg layer industry supports it because more than 77% of cases in commercial poultry have been in layer operations. The conclusion is that vaccination of layers is the likely first use, and trade rules on vaccinated products govern how far it goes.

Government funding supports the supply side. In March 2025 USDA set out a five part plan that included USD 100 million for vaccine research, USD 500 million for biosecurity and USD 400 million in financial relief for affected farmers, and it plans to rebuild a poultry vaccine stockpile that was first built after the outbreaks of 2014 and 2015 and never used. Medgene had met the requirements of the USDA platform technology guidelines for an avian influenza vaccine in dairy cattle, with Elanco to sell and distribute it, and the vaccine was in final review for a conditional licence. The conclusion is that public funding and platform rules are shortening development time, and dairy cattle are a second species that opens a new market.

African swine fever is the second large programme. Vietnam announced production of the first African swine fever vaccine on 1 June 2022, after the disease reached all 63 provinces and municipalities in 2019 and more than 5.7 million pigs were culled, and the authorisation of the live attenuated AVAC ASF LIVE vaccine was reported in July 2023. The conclusion is that Asia has moved first on a vaccine for swine, and the safety and traceability of live vaccines remain the questions that regulators in other regions will ask.

The brief treats livestock vaccines as an accelerating signal with a nine year horizon to 2035. It identifies which species, regions and operators scale first and what each means for animal health companies, specialist makers, governments and producers. It is a focused 102-page decision brief that presents an indicative trajectory rather than a segmented market model.

A livestock vaccine is a biological product that protects poultry, pigs, cattle or small ruminants from infectious disease, and it can be killed, live attenuated or made on a platform that is updated for new strains.

Conditional licences let a vaccine be sold on evidence of safety and a reasonable expectation of efficacy during an emergency.

Performance depends on the match to circulating strains and on the ability to tell vaccinated from infected animals.

Uses are poultry, swine and cattle, in routine programmes and in outbreak response.

The limits are trade restrictions on vaccinated animals, opposition from exporting sectors, safety of live vaccines and the separate approval needed to deploy a licensed vaccine. The period turns on government decisions on vaccination.

The livestock vaccines market, covering vaccines for poultry, swine, cattle and small ruminants, including avian influenza and African swine fever programmes, is valued at USD 9.0–11.0 billion in 2026 and is projected to reach USD 17.99–21.99 billion by 2035, at a CAGR of 8%.

The 2026 base rests on routine vaccine sales for poultry, swine and cattle, with early sales of avian influenza and African swine fever vaccines. Growth then follows government stockpiles, deployment decisions and wider licensing.

The forecast is sensitive to outbreak trends, trade rules on vaccinated animals and the pace of deployment approvals. Regionally, Asia-Pacific leads on swine and poultry volumes, North America on licensing and government funding, and Europe on poultry vaccination policy.

The base case assumes layer vaccination is approved in the major egg producing countries and African swine fever vaccines widen in Asia, giving the inflection in 2030. An accelerated case assumes trade partners accept vaccinated products, bringing the inflection to 2028 and lifting the 2035 value to the top of the range. A delayed case assumes continued opposition from exporting sectors and safety concerns over live vaccines, holding growth at the bottom of the range.

Growth drivers

• Avian influenza outbreaks in poultry and dairy cattle.
• African swine fever spread.
• Government vaccine stockpiles and research funding.
• Conditional licensing routes.

Enablers

• Platform technology guidelines.
• Distribution partnerships.
• Veterinary services and surveillance.
• Public research programmes.

Restraints and barriers

• Trade restrictions on vaccinated animals.
• Opposition from exporting sectors.
• Safety of live vaccines.
• Separate approval for deployment.

The direction of livestock vaccines is set by outbreaks of avian influenza and African swine fever, government stockpiles and funding, trade rules and export concerns, platform technologies and conditional licences, and producer economics.

The key participants in livestock vaccines include Zoetis Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Elanco Animal Health Incorporated, Ceva Santé Animale S.A., Phibro Animal Health Corporation, Laboratorios Hipra, S.A., Virbac SA, Vetoquinol SA, Biogénesis Bagó S.A., Medgene Labs, Inc., Indian Immunologicals Limited, Hester Biosciences Limited, Jinyu Bio-Technology Co., Ltd., China Animal Husbandry Industry Co., Ltd., National Veterinary Joint Stock Company, AVAC Vietnam Joint Stock Company, Kyoritsu Seiyaku Corporation, Bioveta, a.s., Huvepharma EOOD, University of Connecticut, The Pirbright Institute, Wageningen University & Research, Iowa State University, Kansas State University, U.S. Department of Agriculture, European Medicines Agency, European Food Safety Authority, European Commission, Ministry of Agriculture and Rural Affairs of China, Ministry of Agriculture and Livestock of Brazil, Department for Environment, Food and Rural Affairs, Department of Animal Health of Vietnam, World Organisation for Animal Health, Food and Agriculture Organization, National Chicken Council, United Egg Producers, National Pork Producers Council, HealthforAnimals, AnimalhealthEurope and Gates Foundation.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as livestock vaccines mature.

Zoetis, Merck & Co., Boehringer Ingelheim and Ceva lead among animal health majors with licensed poultry and swine vaccines, Medgene leads on the dairy cattle avian influenza vaccine, and NAVETCO and AVAC lead on African swine fever vaccines in Vietnam. Competitive intensity is moderate in 2026 and rises as conditional licences are converted to full licences.

Where value migrates.

In 2026 value sits with holders of conditional licences and with makers of African swine fever vaccines, because licensed products are the scarce assets. By 2031 it moves toward suppliers to government programmes, because stockpiles and deployment decisions create volume. By 2035 it settles in routine disease control portfolios that combine several vaccines and diagnostics. Margins hold for makers of updated platform vaccines and narrow for makers of older single strain products.

The signals converge on licences ahead of deployment. A conditional US licence, public funding for vaccine research and an authorised swine fever vaccine support growth, while trade restrictions, opposition from exporting sectors and the separate approval needed for deployment limit the pace.

Structural limits show where progress could slow: trade restrictions on vaccinated animals, opposition from exporting sectors, safety of live vaccines, and separate approval for deployment. The brief therefore tracks four indicators: deployment decisions, new licences, outbreak counts, and trade agreements on vaccinated products.

Layer hens first, then swine in Asia, then dairy cattle and broilers are the expected order of adoption.